DGX: Haystack MRD demonstrates robust clinical performance in DYNAMIC colorectal cancer trials
Guardant Health said Haystack MRD demonstrated robust clinical performance in a specimen cohort from the DYNAMIC colorectal cancer trials.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.